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Gene therapy for cystic fibrosis using non-viral, plasmid-based formulations has been the subject of 
intensive research for over two decades but a clinically viable product has yet to materialise in large part 
due to inefficient transgene expression. Minicircle DNA give enhanced and more persistent transgene 
expression compared to plasmid DNA in a number of organ systems but has not been assessed in the 
lung. In this study we compared minicircle DNA with plasmid DNA in transfections of airway epithelial 
cells. In vitro, luciferase gene expression from minicircles was 5–10-fold higher than with plasmid DNA. 
In eGFP transfections in vitro both the mean fluorescence intensity and percentage of cells transfected 
was 2–4-fold higher with minicircle DNA. Administration of equimolar amounts of DNA to mouse lungs 
resulted in a reduced inflammatory response and more persistent transgene expression, with luciferase 
activity persisting for 2 weeks from minicircle DNA compared to plasmid formulations. Transfection 
of equal mass amounts of DNA in mouse lungs resulted in a 6-fold increase in transgene expression in 
addition to more persistent transgene expression. Our findings have clear implications for gene therapy 
of airway disorders where plasmid DNA transfections have so far proven inefficient in clinical trials.
Lung diseases are a major cause of morbidity including genetic diseases, such as cystic fibrosis (CF), primary 
ciliary dyskinesia (PCD), surfactant protein B (SPB)-deficiency and alpha 1-antitrypsin (A1AT) –deficiency1. 
The lung is an attractive organ for gene therapy of these diseases given its accessibility allowing for vector delivery 
by inhalation. CF is the most common respiratory genetic disease and, since the cystic fibrosis transmembrane 
conductance regulator gene (CFTR) was identified in 19892, it has become one of the most intensely studied 
diseases in the field of gene therapy1,3. A number of human clinical trials have been conducted4–11 but clinically 
viable gene therapy treatments for CF or other genetic lung disorders have yet to materialise. This lack of clinical 
efficacy has been in large part due to inefficient transgene expression resulting from the mucociliary barriers that 
the respiratory system has evolved to clear inhaled foreign particles.
More recently, PCD has been proposed as a candidate respiratory disease for treatment by gene therapy. PCD, 
like CF, affects the ciliated airways from the bronchi to the bronchioles and thus faces many of the same challenges 
in achieving therapeutic levels of lung transfection, although it is genetically far more heterogeneous than CF 
with 30 disease-causing genes identified to date12. Mutations in the DNAH5 and DNAI1 genes, which both code 
for outer dynein arm proteins essential for normal cilia motility, are the most common cause of PCD together 
accounting for around 30% of patients13,14. Proof of concept for PCD gene therapy has been demonstrated in vitro 
in human cells from patients with mutations in the DNAI1 gene15 and murine cells from a mouse model of PCD 
where the gene for the outer dynein arm protein Dnaic1 (murine homolog of human DNAI1) was mutated16.
Gene therapy for lung diseases will likely require repeated administration several times a year for the lifetime 
of the patient given the limited lifespan of airway epithelial cells. Therefore, non-viral gene delivery formulations 
are best suited for this application owing to their low toxicity and low immunogenicity allowing repeated dosing. 
In addition, non-viral formulations can be delivered by nebulisation and may be produced at a large-scale to 
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clinical grade. However, as noted in clinical trials of CF gene therapy, with liposomal and polymeric formulations, 
clinically relevant levels of gene transfer have proven difficult to achieve.
We have focused our recent research on an improved nanocomplex formulation of lipids and peptides in 
which these components interact synergistically to enhance transfection efficiency17. We have developed nano-
complex formulations targeted to the airway epithlium and found a nanocomplex termed LED-1 efficiently trans-
fected airway epithelial cells in vivo18. LED-1 is formulated with a cationic Liposome made up of DHDTMA/
DOPE lipids, a cationic peptide with residues K16GACSERSMNFCG (referred to as peptide E) and plasmid DNA. 
The nanocomplexes are targeted to the airway epithelial cells via peptide ligands18,19 while the lipid components 
help to overcome endosomal barriers to transfection producing greatly improved levels of epithelial specific trans-
fection in vitro and in vivo20. Towards developing optimal formulations and protocols for airway epithelial gene 
transfer, we then optimised the methods of nebulised delivery to the conducting airways in mice21 and pigs22.
In addition to improving the delivery formulation, we are now focusing on optimisation of the DNA payload 
itself. Elements of the plasmid DNA payload that have been optimised to either enhance or prolong transgene 
expression have included the promoter, enhancer elements and polyadenylation signals as well as the removal of 
all CpG motifs to reduce inflammation23–27. However, plasmids also contain a bacterial backbone consisting of 
prokaryotic replication origin sequences and antibiotic resistance genes to allow for easy propagation and purifi-
cation of plasmid DNA which are not necessary for the gene therapy formulation.
Recently a number of groups have removed the bacterial backbone from plasmid DNA to produce minicircle 
DNA by adding recombination sequences between the transgene expression cassette and the bacterial backbone, 
followed by recombination in E.coli to produce minicircles28–30. Several studies have shown that minicircle DNA 
provide enhanced transgene expression in a variety of organ systems in vivo including the liver31–33, heart34,35 and 
skeletal muscle35 but minicircles have not been assessed for airway gene delivery. In this study we have produced 
a number of minicircles containing reporter transgenes and the 14 kb DNAH5 cDNA encoding an outer dynein 
arm protein involved in PCD, the largest minicircle produced to date. We assessed whether minicircles could 
enhance transgene expression in airway epithelial cells in vitro and in vivo in mice. Furthermore, we have assessed 
the persistence of transgene expression in vivo, and assessed the inflammatory response to minicircle and plasmid 
DNA transfections.
Materials and Methods
Materials. Peptide K16GACSERSMNFCG19 was synthesised by China Peptide Co., Ltd (Shanghai, China), 
and dissolved in endotoxin-free water (Sigma-Aldrich, Dorset, UK) to 10 mg/mL. Liposome consisted of 
1-Propanaminium, N,N,N-trimethyl-2,3-bis(11Z-hexadecenyloxy)-chloride (DHDTMA chloride; Avanti Polar 
Lipids; Alabama, USA) with dioleoylphosphatidylethanolamine (DOPE; Avanti Polar Lipids; Alabama, USA) 
formulated at a 1:1 weight ratio and dissolved in sterile water to give a 2 mg/mL liposome suspension.
Cloning and minicircle production. Minicircle producer plasmids expressing enhanced green fluores-
cent protein (eGFP), firefly luciferase (Luc2), and DNAH5 were produced by cloning into the commercial plas-
mid pMC.BESPX-MCS2 (Cambridge Biosciences; Fig. 1). To do this, the EF1α promoter from pCpGfree-LacZ 
(Invivogen, Toulouse, France) was cloned into pMC.BESPX-MCS2 and Luc2 gene and SV40 polyadenylation sig-
nal from pGL4.10 (Promega, Southampton, UK) sub-cloned to produce pMC.Luc2. Alternatively, SV40 polyade-
nylation signal from pCpGfree-LacZ was sub-cloned into pMC.EF1α .MCS and eGFP cDNA from pEGFP-N1 
Figure 1. Schematic of the cloning of minicircle producer plasmids. Minicircle producer plasmids coding for 
eGFP (pMC.eGFP), DNAH5 (pMC.DNAH5) and firefly luciferase (pMC.Luc2) were produced by sub-cloning, 
sequentially, the EF1α promoter, SV40 polyadenylation signal and transgene cDNA sequences into the empty 
minicircle producer plasmid pMC.BESPX-MCS2.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:23125 | DOI: 10.1038/srep23125
(Clontech, Saint-Germain-en-Laye, France) sub-cloned to produce pMC.eGFP. DNAH5 cDNA was PCR ampli-
fied from reverse transcribed RNA (Omniscript RT kit; Qiagen, Crawley, UK) extracted from ciliated human 
airway epithelial cells. Given the size of DNAH5, the full-length cDNA was cloned as three overlapping segments 
each of which were TOPO cloned into pCR-XL-TOPO plasmid (Life Technologies, Paisley, UK). The cDNA 
was flanked with KpnI and SalI sites and naturally occurring AfeI and SexAI sites were utilised to reconstruct 
the full-length DNAH5 cDNA which was subsequently sub-cloned into pMC.EF1α .MCS.SV40pA to produce 
pMC.DNAH5. Minicircle DNA (MC) was produced from the minicircle producer plasmid (pMC) as previously 
described30 and agarose gel electrophoresis showed no detectable plasmid contamination in minicircle DNA 
preparations (Figure S1).
Cell culture. 16HBE14o- cells (kind gift from Professor Dieter Gruenert, San Francisco36) were cultured 
in complete media consisting of Eagle’s Minimal Essential Medium (MEM; Sigma-Aldrich, Dorset, UK) sup-
plemented with 10% (v/v) foetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mmol/l 
L-glutamine and incubated in humidified 5% CO2 at 37 °C.
In vitro transfections. Cells were seeded in 96-well plates at a density of 20,000 cells per well and incu-
bated in humidified 5% CO2 at 37 °C for 24 hours. For luciferase assay experiments, cells were seeded in black 
plates with clear bottoms (Fisher Scientific UK, Leicestershire, UK). All complexes were prepared in OptiMEM 
(Life Technologies, Paisley, UK). LED-1 complexes were prepared at a 0.75:4:1 weight ratio of liposome: peptide: 
plasmid/minicircle DNA as optimised previously18. Complexes were formulated to a plasmid/minicircle DNA 
concentration of 10 μg/mL and prepared by first mixing the cationic liposome and peptide solutions followed 
by addition of the DNA solution. Formulations were incubated at room temperature for 30 minutes to allow 
for complex self-assembly and 25 μL (250 ng for plasmid DNA or equal mass minicircle DNA) added to cells in 
175 μL complete media, centrifuged at 378 × g for 5 minutes and incubated in humidified 5% CO2 at 37 °C for 24 
or 48 hours for luciferase and flow cytometry assays, respectively. Where appropriate, complexes were diluted in 
OptiMEM to equimolar amounts of DNA before incubating with cells.
Luciferase assay following in vitro transfection. Cells were washed with 1x PBS 24 hours following 
transfection and lysed with 20 μL Reporter Lysis Buffer (Promega, Southampton, UK) for 20 minutes at 4 °C then 
− 80 °C for at least 30 minutes followed by thawing at room temperature. Luciferase activity was assessed using 
the Luciferase Assay System (Promega, Southampton, UK) on a FLUOstar Optima plate reader (BMG Labtech, 
Aylesbury, UK). The results were standardised for protein content using the Bradford protein assay (Bio-Rad, 
Hertfordshire, UK) and expressed as relative luminescence units per mg of protein (RLU/mg). Assessment of 
luciferase activity at 24 hours was chosen as firefly luciferase is known to have a short half-life (3h)37 and expres-
sion following lung gene delivery in vivo has been shown to be maximal at 24 hours38,39.
Flow cytometry. Adherent cells in 96-well plates were detached using 50 μL Trypsin-EDTA (Sigma-Aldrich, 
Dorset, UK) and re-suspended with 150 μL DPBS (Sigma-Aldrich, Dorset, UK). Cells were then acquired with a 
BD FACSArray flow cytometer (BD Biosciences, Oxford, UK) and analysis was performed with FlowJo software 
v. 8.8.3 (Tree Star Inc., Olten, Switzerland).
qRT-PCR. Cells were harvested 48 hours following transfection and homogenised with Qiagen shredders 
(Qiagen, Crawley, UK). Total RNA was isolated from the homogenate using a Qiagen RNeasy Mini kit (Qiagen, 
Crawley, UK) and DNAse digested (TURBO DNAse; Life Technologies, Paisley, UK). cDNA was then synthesised 
with 2 μg of total RNA as the template for Omniscript reverse transcriptase (Omniscript RT kit; Qiagen, Crawley, 
UK) in a 1 hour reaction at 37 °C and subsequently used in a qPCR reaction containing Platinum Quantitative 
PCR SuperMix-UDG w/ROX (Life Technologies, Paisley, UK) and TaqMan Gene Expression Assay primers and 
probe (Assay ID- DNAH5, Hs00292485_m1). Real-time quantitative PCR was performed using an ABI PRISM 
7000 Sequence Detection System. The PCR reaction cycles used were 50 °C for 2 minutes, 95 °C for 10 minutes, 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Fluorescence data was collected at the end of each 60 °C 
reaction and relative expression levels calculated using the delta-delta Ct (2−ΔΔCt) method40.
For qPCR of plasmid and minicircle DNA, cells were harvested 48 hours following transfection and DNA 
extracted with DNeasy Blood & Tissue Kit (Qiagen, Crawley, UK). Purified DNA was then used in a qPCR reac-
tion as described above for synthesised cDNA.
In vivo transfections. All procedures were approved by UCL animal care policies and were carried out 
under Home Office Licenses issued in accordance with the United Kingdom Animals (Scientific Procedures) Act 
1986 (UK). 5–6 week-old immunocompetent female CD1 mice (Charles River, Margate, UK) were used for all 
in vivo experiments. Complexes were prepared as described for in vitro transfections except complexes were made 
in pyrogen free water (Baxter, Berkshire, UK) to a final DNA concentration of 333.3 μg/mL and 50 μL (16.7 μg 
for plasmid DNA or equal mass minicircle DNA) was given by oropharyngeal instillation following gaseous 
isoflurane induced anaesthesia. Where appropriate, complexes were diluted in pyrogen free water to equimolar 
amounts of DNA before oropharyngeal instillation.
Luciferase assay following in vivo transfection. 24 hours, 7 days or 14 days following oropharyngeal 
instillation of nanocomplexes mice were culled and their lungs extracted and snap frozen. Lungs were weighed 
and immersed in 400 μL of ice cold reporter lysis buffer (Promega, Southampton, UK) per 100 mg of tissue and 
homogenised on ice using a T 10 basic Ultra Turrax homogeniser (IKA, Staufen, Germany) and then centrifuged 
at 14,170 × g for 10minutes at 4 °C. The supernatant was transferred to an autoclaved microfuge tube and cen-
trifuged for a further 10 minutes at 4 °C and luciferase activity was assessed using the Luciferase Assay System 
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(Promega, Southampton, UK) as described above. Results were expressed as relative luminescence units per mil-
ligram of protein (RLU/mg).
Histology. 24 hours following transfection, mouse lungs were inflation-fixed by intratracheal instillation of 
4% (w/v) paraformaldehyde in PBS post-mortem and extracted lungs processed and stained with haematoxylin 
and eosin to demonstrate tissue architecture and inflammatory cell infiltration as previously described41.
Bronchoalveolar lavage fluid analysis. 24 hours following transfection, mice were culled and bronchoal-
veolar lavage fluid collected and processed for cytokine and chemokine quantification as previously described42. 
The presence of inflammatory cytokines in BALF was assessed and quantified using the Cytokine Mouse 10-Plex 
Panel (Life Technologies, Paisley, UK) and plates were read using a Bio-Plex 100 reader (Bio-Rad, Hertfordshire, 
UK) and data collected with Bio-Plex Manager software (v 4.1.1; Bio-Rad, Hertfordshire, UK).
Statistical analysis. Data are mean values ± standard error of the mean (SEM) for in vitro studies and 
median with all data points shown for in vivo studies. For in vitro studies Student’s t-test was used to assess statis-
tical significance. For in vivo studies where normal distribution was not observed non-parametric Kruskal-Wallis 
test followed by Dunn’s multiple comparison test was used to assess statistical significance. Significance levels 
were set at p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; NS = not significant.
Results
Minicircle DNA production. Minicircle DNA (MC) was produced from minicircle producer plasmids 
(pMC) as previously described30. To assess the purity of minicircle DNA 500 ng of both plasmid and minicircle 
DNA preparations were digested with single cutting restriction enzymes and electrophoresed on a 1% ethidium 
bromide stained agarose gel and visualised under UV light. We found no detectable plasmid contamination in 
minicircle DNA preparations suggesting efficient minicircle production (Figure S1).
In vitro transfections. 16HBE14o- cells36 were used for in vitro studies as a representative cell type of the 
bronchial epithelium, the target for gene therapy of CF and PCD. Cells were transfected using a non-viral vector 
(LED-1) previously optimised for airway gene delivery to mammalian cells in vitro and in vivo18. Cells were trans-
fected with varying amounts of minicircle and plasmid DNA carrying either the firefly luciferase gene (MC.Luc2 
and pMC.Luc2, respectively) or the eGFP gene (MC.eGFP and pMC.eGFP, respectively). Cells transfected with 
minicircle DNA showed 5–10-fold higher levels of luciferase activity than plasmid DNA (Fig. 2a; p < 0.001) at 
equivalent doses. Flow cytometry analysis of eGFP transfected cells revealed a 2.5 to 4-fold increase in the percent-
age of cells expressing eGFP after transfection with minicircle DNA compared to plasmid DNA (Fig. 2b; p < 0.001 
with all doses tested). Furthermore, the mean fluorescent intensity of cells transfected with eGFP minicircle 
DNA was 2.5 to 3-fold higher than cells transfected with plasmid DNA (Fig. 2c; p < 0.001with all doses tested). 
Fluorescence microscopy observations provided visual confirmation of the flow cytometry data (Figure S2).
Encouragingly, when the commercial transfection reagents Lipofecatmine 2000 and 25 kDa branched pol-
yethylenimine (PEI) were used to transfect 16HBE14o- cells minicircle DNA showed 3–6-fold higher levels of 
luciferase activity than plasmid DNA (Figure S3; p < 0.001).
Using the LED-1 formulation, transfection of the 14 kb DNAH5 cDNA, which encodes a protein in the ciliary 
outer dynein arm, resulted in 66.0 ± 11.8% higher levels of vector specific mRNA expression from the minicircle 
MC.DNAH5 than the plasmid pMC.DNAH5 (Fig. 3a; p < 0.01) when the same number of DNA molecules was 
transfected into 16HBE14o- cells.
We have previously shown a positive correlation between DNA size and the diameter of liposome:pep-
tide:DNA nanoparticles43. The diameter of nanoparticles is known to affect their cellular uptake44 potentially 
affecting transgene expression. With DNAH5 coding DNA the plasmid was 19.1 kb compared to 15.1 kb for the 
minicircle and we found nanoparticles formulated with pMC.DNAH5 plasmid had a diameter of 92.9 ± 0.6 nm 
compared to 110.5 ± 1.1 nm for LED-1 formulated with MC.DNAH5 minicircle DNA (Figure S4; p < 0.001). 
Both formulations yielded nanoparticles with a highly positive surface charge of 39.0 ± 0.4 mV and 35.4 ± 0.5 mV 
respectively (Figure S4; p < 0.01). Similarly, LED-1 complexes formulated with firefly luciferase and eGFP coding 
plasmid and minicircle DNA were around 100 nm and had a highly positive surface charge of between 35–40 mV 
(Figure S4). Whilst statistically significant these small differences should not have affected the uptake of LED-1 
particles, and therefore transfection efficiency, given that the sizes were well below the 200 nm upper limit for 
clathrin mediated endocytosis44. Supporting this hypothesis, using qPCR analysis of DNA extracted from trans-
fected 16HBE14o- cells we confirmed that equal numbers of plasmid and minicircle DNA molecules were found 
in 16HBE14o- cells transfected with equimolar amounts of pMC.DNAH5 plasmid and MC.DNAH5 minicircles 
(Fig. 3b).
In vivo transfections. Next we compared reporter gene expression from minicircle and plasmid DNA in 
vivo. Murine lungs were transfected by oropharyngeal instillation with a single dose of LED-1 complexes for-
mulated with 16.7 μg of plasmid DNA (pMC.Luc2) or minicircle DNA (MC.Luc2). The lungs were harvested 
24 hours later and lung extracts assayed for luciferase activity. Minicircle DNA gave a 6.5-fold higher median 
level of transgene expression than plasmid DNA (Fig. 4; median value of 8115.9 RLU/mg for minicircle DNA and 
1249 RLU/mg for plasmid DNA; p < 0.01). However, in contrast to in vitro transfections, there was no significant 
difference in transfection efficiency using equimolar amounts of plasmid (16.7 μg) and minicircle DNA (7.1 μg) 
in vivo (Fig. 4; median value of 2215 RLU/mg for minicircle DNA and 1249 RLU/mg for plasmid DNA).
We then assessed transgene persistence following a single dose of LED-1 complexes formulated with plasmid 
DNA (pMC.Luc2) or minicircle DNA (MC.Luc2). Luciferase assays of lung extracts were performed at 1, 7 and 
14 days following a single dose of luciferase gene delivery. The median level of luciferase activity was 5674.9 
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RLU/mg 1 day following oropharyngeal instillation of 16.7 μg of pMC.Luc2 but at 7 and 14 days luciferase activity 
was undetectable in 5/7 mice (Fig. 5; p < 0.01). In contrast, following instillation of 7.1 μg (equimolar) and 16.7 μg 
(equal mass) of MC.Luc2 luciferase expression remained detectable in all mice at 14 days following transfec-
tion (Fig. 5) although there was a significant loss of luciferase expression between 1 day and 14 days following 
transfection (Fig. 5; for MC.Luc2 (equimolar) median value of 13676.2 RLU/mg at day 1 falls to 631.0 RLU/mg 
at ay 14 p < 0.05; for MC.Luc2 (equal mass) median value of 38030.7 RLU/mg at day 1 falls to 719.6 RLU/mg at 
ay 14 p < 0.01). Thus, equal weight or equimolar doses of minicircle DNA with the same cDNA and regulatory 
elements gives more persistent transgene expression than plasmid DNA.
Minicircle toxicity compared to plasmid DNA formulations. LED-1 nanocomplexes formulated with 
minicircle DNA contain less DNA, as well as liposome and peptide, than complexes formulated with equimolar 
amounts of plasmid DNA. We hypothesised the lower mass of DNA may translate to reduced toxicity in vivo. 
24 hours after LED-1 transfections with luciferase encoding pMC.Luc2 or MC.Luc2 lungs were fixed by perfusion 
with 4% PFA and processed for H&E staining. Lungs of mice receiving the vehicle control, MilliQ water, showed 
no signs of inflammation or cellular infiltration by histology (Fig. 6a). In contrast, the lungs of mice transfected 
with plasmid or minicircle DNA showed evidence of patchy, mild peribronchial inflammation which was pre-
dominantly of a monocyte/macrophage nature. However, there were no clear differences when comparing plas-
mid and minicircle transfections (Fig. 6b–d).
Toxicity was further assessed by quantification of cytokine release. Bronchoalveolar lavage fluid (BALF) was 
obtained 24 hours following transfections with pMC.Luc2 plasmid or MC.Luc2 minicircles. Levels of IL-12 and 
IFN-γ were similar in BALF from mice receiving LED-1 vectors containing 16.7 μg of plasmid or minicircle DNA 
(Fig. 7a–b). Transfections with plasmid DNA or equimolar amount of minicircle yielded no detectable TNF-α 
expression in BALF which contrasted with a median of 67.22pg/mL following an equal mass minicircle trans-
fection (Fig. 7c; p < 0.05). We also assessed levels of GM-CSF, IL-1β , IL-2, IL-4, IL-5, IL-6 and IL-10 and all were 
undetectable in all BALF samples. Encouragingly, all cytokines were undetectable in BALF from lungs of mice 
transfected with 7.1 μg of minicircle DNA (equimolar).
Figure 2. Transgene expression following in vitro transfections. 16HBE14o- cells were transfected with 
minicircle DNA (green line) or plasmid DNA (red line) carrying the firefly luciferase gene (a) or the eGFP 
gene (b,c). For eGFP transfections both the percentage of positive cells (b) and the MFI (c) were assessed. 
***P < 0.01; Student’s t-test used to assess significance. Values are background subtracted and displayed as 
mean ± SEM.
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Discussion
Gene delivery to the airway epithelium has been investigated for a number of diseases with most progress being 
made in the context of CF lung disease. We have previously shown that a non-viral formulation of a cationic 
Figure 3. DNAH5 expression following in vitro minicircle and plasmid DNA transfections. 16HBE14o- 
cells were transfected with pMC.DNAH5 or MC.DNAH5 complexed into LED-1 particles and the relative 
amounts of DNAH5 (a) mRNA and (b) vector specific DNA quantified using qPCR and the 2- ΔΔCt method. 
NS, not significant; **P < 0.01; Student’s t-test used to assess significance. Values are mean ± SEM.
Figure 4. Transgene expression following in vivo minicircle and plasmid DNA transfections. Luciferase 
activity 24 hours following oropharyngeal instillation of CD1 mice with LED-1 complexes containing pMC.
Luc2 plasmid DNA or MC.Luc2 minicircle DNA at either equimolar or equal mass quantities. *P < 0.05; 
**P < 0.01; Kruskal-Wallis test followed by Dunn’s post-test analysis to assess significance. Values are 
background subtracted and bar represents median RLU/mg.
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DHDTMA/DOPE liposome and a cationic targeting peptide complexed with plasmid DNA efficiently transfected 
the airway epithelium of mice and pigs18,21,22. The peptide component is important for the formation of small 
and stable nanoparticles and receptor targeting whilst the liposome component is vital for endosomal escape to 
prevent degradation of the DNA payload17,20.
In this study we have shown that LED-1 formulations containing minicircle DNA can provide greater and 
more persistent transgene expression which could increase the prospect of successful gene therapy for airway 
diseases. Irrespective of whether LED-1, Lipofectamine 2000 or 25 kDa branched PEI was used as the transfection 
reagent, we have demonstrated that minicircle DNA enhanced transgene expression in airway cells in vitro. Other 
reports using minicircle DNA in a variety of human cell lines similarly showed 2–3 fold higher levels of transgene 
expression with minicircle DNA compared to plasmid DNA45. Our eGFP expression studies showed that both the 
percentage of transfected cells and the amount of protein produced was higher when using minicircle DNA. As in 
previous studies45, enhanced transgene expression was seen when transfecting equimolar amounts of minicircle 
and plasmid DNA, confirmed by qPCR analysis, highlighting that enhanced expression from minicircle DNA 
was not due to an increased number of transgene expression cassettes. Previous reports have demonstrated an 
Figure 5. Transgene expression following in vivo minicircle and plasmid DNA transfections. Luciferase 
activity at 1, 7 and 14 days following a single dose of LED-1 complexes containing pMC.Luc2 plasmid DNA or 
MC.Luc2 minicircle DNA at either equimolar or equal mass quantities delivered by oropharyngeal instillation 
of CD1 mice. NS, not significant; *P < 0.05; **P < 0.01; Kruskal-Wallis test followed by Dunn’s post-test 
analysis to assess significance. Values are background subtracted and bar represents median RLU/mg.
Figure 6. H&E staining of mouse lungs following in vivo minicircle and plasmid DNA transfections. H&E 
stained CD1 mice lung sections following oropharyngeal instillations of (a) water as a vehicle control, LED-1 
vectors containing (b) pMC.Luc2, (c) MC.Luc2 at an equal mass to pMC.Luc2 and (d) MC.Luc2 equimolar to 
pMC.Luc2. Scale bars are 100 μm.
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inverse correlation between plasmid DNA size and transfection efficiency, despite equimolar amounts of DNA 
being transfected46,47. More recent studies have implicated the length of DNA sequences outside of the transgene 
expression cassette, irrespective of sequence origin, in lowering levels of transgene expression and persistence48. 
Minicircles have very little extragenic sequences so explaining their superiority over plasmid DNA which have 
sizeable bacterial backbones (~4 kb in this study).
Importantly for PCD gene therapy, we have also shown enhanced transgene expression with minicircle DNA 
when transfecting equimolar amounts of the large 14 kb DNAH5 cDNA. Here the plasmid DNA was 19.1 kb 
Figure 7. Cytokine response in BALF following in vivo minicircle and plasmid DNA transfections. 
Concentration of (a) IL-12, (b) IFN-γ and (c) TNF-α cytokines in BALF following instillation of LED-1 vectors 
containing luciferase encoding minicircle or plasmid DNA. Water was used as a vehicle control. *P < 0.05; 
Kruskal-Wallis test followed by Dunn’s post-test used to assess significance. Bar represents median.
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compared to 15.1 kb for the minicircle. To our knowledge this is the largest minicircle produced to date and 
provides evidence that the attB-attP recombination system for minicircle production30 can accommodate large 
DNA sequences.
In contrast to in vitro studies, no significant differences in the initial levels of transgene expression were seen 
here in vivo comparing equimolar amounts of plasmid and minicircle DNA transfections. These findings are 
consistent with previous observations in the mouse liver31,49 where the major advantage of minicircle DNA was 
more persistent transgene expression. Similar to previous studies we found transgene expression from plasmid 
and minicircle DNA fell at 7 days post-transfection but the fall was greater with plasmid DNA and transgene 
expression from minicircles appeared to have stabilised49 with no significant differences found when compar-
ing transgene expression 7 and 14 days post-transfection. Luciferase activity was undetectable, in most cases, 
at 7 and 14 days following plasmid DNA transfection in contrast to minicircle DNA where luciferase activity 
was detectable in all mice 14 days post-transfection. As such, whilst transgene expression levels were similar 
24 hours following transfection, minicircle transfections gave more prolonged expression. This persistent trans-
gene expression could have resulted from a greater loss of plasmid DNA, increased silencing of plasmid DNA or 
a mixture of both. Viecelli et al.33, and Chen et al.31, found no difference in the number of plasmid and minicircle 
DNA molecules in the liver despite more persistent transgene expression using minicircle DNA. Further studies 
highlighted extragenic DNA sequences above 500bp can induce transgene silencing48 in the liver which was due 
to chromatin-linked silencing of transcription50. Whether this mechanism explains the more persistent transgene 
expression we observed in mouse airways needs further investigation.
Lung transfections with the same mass of minicircle or plasmid DNA showed an approximately 6.5-fold 
increase in expression at 24 hours post-transfection with minicircle DNA. The MC.Luc2 minicircle at 2.9 kb used 
in this study was less than half (42.8%) the size of the pMC.Luc2 plasmid at 6.9 kb, therefore, in equal mass trans-
fections there are 2.3-times more copies of the luciferase transgene in the minicircle transfection compared to 
the plasmid. The increased copies of luciferase transgene with minicircle transfection could explain, at least in 
part, the enhanced levels of transgene expression observed. However, it is of note that transgene expression was 
6.5-fold greater with minicircle compared to plasmid DNA but only 2.3-times more luciferase transgenes were 
transfected with minicircle DNA. As such, it is unlikely that the 2.3-fold increase in the number of transgene 
expression cassettes fully explains the significantly higher increase in luciferase expression observed with equal 
mass minicircle transfections.
The LED-1 vector is formulated at a constant 0.75:4:1 mass ratio of liposome: peptide: DNA therefore in equi-
molar transfections the dose of all three components is lower when using minicircles. As such, we hypothesised 
that this lower dose would result in reduced toxicity. To test this hypothesis we assessed toxicity by histological 
analysis and cytokine levels in BALF. Histological analysis showed foci of mild inflammation in all transfected 
mice, consistent with our previous studies using the LED-1 vector18, and we found no obvious differences in 
severity comparing plasmid and minicircle DNA transfections. This patchy and localised inflammation has been 
associated with the bolus delivery of vector causing a transient and acute inflammatory response that can be cir-
cumvented by delivery of nebulised formulations51. Indeed when nebulisation was used with the LED-1 vector 
we found no inflammation in treated pigs22 in contrast to when a bolus of vector was administered52. However, to 
ensure accurate dosing a bolus of vector was instilled in this study.
In assessing cytokine levels in BALF we found in transfections with equimolar amounts of minicircle and 
plasmid DNA that 10 different cytokines 24 hours following transfection were all undetectable in BALF of mice 
transfected with minicircle. In contrast, levels of IFN-γ and IL-12 following plasmid DNA transfections were 
elevated compared to minicircle transfections and water controls supporting our hypothesis.
There were no significant differences in IFN-γ and IL-12 levels in BALF when equal masses (16.7 μg) of min-
icircle and plasmid DNA were transfected. However, TNF-α was elevated following transfection with minicircle 
but not plasmid DNA. TNF-α is produced by activated macrophages, monocytes, neutrophils and infected airway 
epithelial cells and is involved in regulating the production of other pro-inflammatory cytokines53–55. Resident 
macrophages in the lung engulf potential pathogens and gene delivery vectors and initiate an innate immune 
response. Immune responses following non-viral gene delivery can typically be attributed to the lipid or peptide 
based vector components51, bacterial DNA sequences as these are rich in unmethylated CpG-motifs56–60 and/or 
antigens from the transgene product, the principle behind DNA vaccines. With regards to the vector compo-
nents the amounts of liposome, peptide and DNA delivered were the same in transfections with equal masses 
of plasmid and minicircle DNA, so these would not have contributed to the elevated levels of TNF-α . Also, the 
minicircle, in contrast to the plasmid, has no plasmid backbone so this also would not explain the elevated TNF-α 
levels following equal mass transfection of plasmid and minicircle DNA. It is possible, therefore, that the elevated 
TNF-α release with minicircle DNA was due to the over 6-fold increase in the amount of foreign luciferase pro-
tein expressed. The development of an immune response to transgene products has been reported previously 
following airway gene delivery51. Whilst the LED-1 vector primarily transfects airway epithelial cells, transgene 
expression in macrophages is also seen18 and greater and more persistent transgene expression would be expected 
to lead to a more robust immune response. Indeed minicircles encoding antigens can be more immunogenic than 
plasmids and provided more effective immunisation in mice61.
The minicircle DNA used in this study has potential for optimisation by further minimising the number 
of CpG-motifs present which has been shown to reduce the numbers of neutrophils, lung macrophages and 
pro-inflammatory cytokines, including IL-12, IFN-γ and TNF-α in BALF, following airway gene transfer in 
mice25–27. In addition, the exchange of the human elongation factor 1- alpha (EF1α ) promoter for human poly-
ubiquitin C (UbC) promoter could provide more enhanced and sustained transgene expression24 bringing the 
prospect of successful airway gene therapy for human diseases ever closer.
In summary, we show that minicircles provide prolonged transgene expression in vivo and, relative to plasmid 
DNA, can be used at equimolar quantities to significantly reduce toxicity and immunogenicity or used at equal 
www.nature.com/scientificreports/
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mass quantities to significantly enhance transgene expression. Our findings thus have clear implications for gene 
therapy of CF, PCD and of other airway disorders where plasmid DNA transfections, despite optimisation, have 
so far proven inefficient in clinical trials62.
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